Express News | Celltrion USA Partners With Express Scripts and Cigna Healthcare to Expand Access to Zymfentra® (Infliximab-Dyyb), the First and Only FDA-Approved Subcutaneous Infliximab on Their Medical Benefit Formulary
Celltrion USA Partners With Express Scripts and Cigna Healthcare to Expand Access to ZYMFENTRA (Infliximab-dyyb), the First and Only FDA-approved Subcutaneous Infliximab on Their Medical Benefit Formulary
US House Committee Sends Warning Letters to CVS, Cigna, UnitedHealth
8 Dividend Growth Stocks for Falling Interest Rates
Cigna PBM Express Scripts to Remove Humira From Many Formularies
Here's How Much $1000 Invested In Cigna 5 Years Ago Would Be Worth Today
Express News | Watching Cencora; Traders Circulate Unconfirmed Analyst Comments Suggesting The Co Has Lost Its Partnership With Cigna To Distribute Branded Humira; Cigna To Transition Distribution Through Its Specialty Distributor Curascript Starting January 2025
Watching Cencora; Traders Circulate Unconfirmed Analyst Comments Suggesting The Co Has Lost Its Partnership With Cigna To Distribute Branded Humira
Is the rebound fading? Goldman Sachs: Hedge funds are selling stocks at the fastest pace in more than two years.
In August, 'smart money' is selling global equities at the fastest pace since March 2022, with the most net selling in North America. Hedge funds are skeptical of the sustainability of the stock market rebound, and geopolitical concerns continue to be worrying. The 'fly' of the economic situation may soon hit the glass windshield.
Billionaire Lee Cooperman Says The Market Is Expensive But The Cigna Group (CI) Is Cheap
The Cigna Group (NYSE:CI) Is a Favorite Amongst Institutional Investors Who Own 89%
Goldman Sachs' Favorite Mutual Funds Positions That Are Overweight the Russell 1000
Cigna Group Is Maintained at Overweight by JP Morgan
JP Morgan Maintains Overweight on Cigna, Raises Price Target to $438
JPMorgan Adjusts Price Target on Cigna Group to $438 From $435, Maintains Overweight Rating
Express News | Cigna : JP Morgan Raises Target Price to $438 From $435
Express News | Cantor Fitzgerald Reiterates Overweight on Cigna, Maintains $400 Price Target
Cigna Analyst Ratings
Express News | The Cigna Group Announces Appearance at the Morgan Stanley 22Nd Annual Global Healthcare Conference
The 'Battleground' Stocks Shorted by Hedge Funds but Owned by Many Long-only Portfolios